The expanding therapeutic uses of thalidomide (TD) are limited by its teratogenic side effects. Although the therapeutic and teratogenic effects may be stereoselectively separable, rapid in vivo racemization of the TD isomers confounds the corroboration of this distinction. Herein we evaluated the potential of fluorothalidomide (FTD), the closest structural analog of TD with stable, nonracemizing isomers, as a model compound for studying stereoselectivity in TD teratogenesis. In contrast to TD, FTD was a potent maternal and fetal toxicant in both rabbits and mice in vivo. Furthermore, FTD rapidly degraded in vivo, presumably via hydrolysis, which in vitro was up to 22-fold faster for FTD than TD. Most critically, in an established rabbit embryo culture model for TD teratogenesis, FTD did not initiate the limb bud embryopathies observed with TD. The chemical instability and strikingly different maternal and developmental toxicological profiles of FTD and TD make FTD an unsuitable compound for studying stereoselective mechanisms of TD teratogenesis.
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Thalidomide (TD) possesses valuable pharmacological properties making it useful in the treatment of a number of inflammatory and immune-mediated diseases as well as cancers (Franks et al., 2004) but is also a well-known potent human teratogen (Lenz, 1988; Schuler-Faccini et al., 2007) . TD (a-phthalimidoglutarimide) , clinically used as a racemic mixture, is composed of two stereoisomers, R-TD and S-TD, which differ solely in the spatial arrangement of atoms around a single chiral carbon center ( Fig. 1) (Franks et al., 2004) . Stereoisomers exhibit identical physical and chemical properties except in the presence of a chiral environment, such as in vivo where protein carriers, metabolic enzymes, receptors, and drug transporters display a greater or exclusive preference for interacting with compounds of a particular spatial configuration (Smith, 2009) . Indeed, stereoselective (isomer dependent) effects are commonly observed with many xenobiotics and/or their metabolites, including the teratogens retinoic acid and valproic acid, and the neurobehavioral teratogen methamphetamine (Smith, 2009) .
Some studies have suggested that the sedative (Eriksson et al., 2000; Fabro et al., 1967b; Hoglund et al., 1998) , immunomodulatory Niwayama et al., 1998; Wnendt et al., 1996) , and teratogenic effects (Blaschke et al., 1979; Fabro et al., 1967b; Heger et al., 1988; Merker et al., 1988) of TD may be stereoselective, raising the intriguing possibility of utilizing its beneficial therapeutic properties without the unwanted teratogenic side effects. Unfortunately, rapid racemization (interconversion) of the TD isomers both in vitro and in vivo (Eriksson et al., 1995) makes it impossible to isolate effects of the individual isomers and precludes a clinical strategy of administrating a single pure TD isomer. This problem is further compounded by the rapid nonenzymatic hydrolysis of TD to an array of products, some of which are teratogenic (Lee et al., 2011a) . Although numerous TD derivatives possessing more potent and stereoselective immunomodulatory and anti-angiogenic properties are available and continue to be developed, the majority have not been tested in animal models; hence, their in vivo toxicities are unknown (Melchert and List, 2007) . Two lead TD derivatives, lenalidomide (Revlimid) and pomalidomide (Actimid), are currently in clinical trials but have nonetheless been associated with reports of teratogenesis (Amin et al., 2009) and are similarly susceptible to racemization in human plasma at a rate similar to that for TD (Teo et al., 2003) , preventing the potential development of a pure isomer devoid of teratogenic effects.
One approach to investigating the stereoselective effects of TD is through the chemical synthesis of analogs with stable, nonracemizing isomers, achieved by replacing the easily abstracted hydrogen atom on the chiral carbon with a more stable atom/chemical group that is a poor leaving group, effectively inhibiting racemization. To date, only two nonracemizing TD analogs have been synthesized, 3-methylthalidomide (Me-TD) and 3-fluorothalidomide (FTD) (Nishimura et al., 1994; Takeuchi et al., 1999) . FTD contains a single fluorine atom substitution on the chiral carbon center and is the closest structural analog of TD ( Fig. 1) (Takeuchi et al., 1999) .
FTD was synthesized over 10 years ago; yet, surprisingly little is known about the potential of this compound as an alternative therapeutic agent to TD. In cell culture, FTD is fivefold more potent than TD as an inhibitor of the proinflammatory cytokine tumor necrosis factor alpha (TNF-a) and displays stereoselectivity , with the S-FTD isomer exhibiting greater inhibitory activity than the R isomer (Takeuchi et al., 1999) . It is not known whether this stereoselectivity is preserved in vivo, whereby the S-FTD isomer would exhibit TNF-a-mediated immunosuppression similar to that for TD, nor is it known whether this isomer is also devoid of teratogenic activity.
Herein we evaluated the potential of FTD to serve as a model compound for studying stereoselectivity in TD teratogenesis using in vivo teratological studies together with in vitro analyses of FTD and TD hydrolysis and studies of FTD embryopathies in embryo culture in both rabbits and mice. Parallel studies employed TD as a positive control. Our results constitute the first characterization of the chemical stability and maternal and developmental toxicity of FTD, which proved to be very different from that of TD, rendering it an unsuitable compound for modeling stereoselective or even molecular mechanisms of TD teratogenesis.
MATERIALS AND METHODS
Chemicals and biochemicals. Racemic TD was a gift from Grunenthal (Aachen, Germany). Racemic FTD was synthesized by one of the authors (N.S.) (Takeuchi et al., 1999) . Hanks' balanced salt solution (HBSS), Waymouth's MB 752/1 medium, fetal bovine serum, and penicillinstreptomycin were obtained from Invitrogen Canada (Burlington, Ontario, Canada Mice. Virgin CD-1 female mice (6-7 weeks, Charles River Canada, St Constant, Quebec, Canada) were housed in plastic cages with corncob bedding on automatic water and air filtering hepafilter racks and maintained in a temperature-controlled room with a 14/10-h light/dark cycle. Food (18% protein rodent diet, 2018, Harlan) and water were provided ad libitum. After 1 week acclimatization, up to three females were time mated with one male either overnight (toxicity and teratology studies) or for a 2-h period (embryo culture studies), and the presence of a vaginal plug the next morning or at the end of the mating period was designated as gestational day (GD) 1 or GD 0, respectively. Inseminated females were separated from the colony and housed together in groups of four or less per cage.
Rabbits. Nonpregnant and virgin pregnant New Zealand white (NZW) female rabbits (3-4 months, Charles River Canada) mated from 7:00 A.M. to 9:00 A.M. by the supplier with the end of the mating session designated as GD 0 were housed one per cage upon arrival and maintained in a temperaturecontrolled room with a 12/12-h light/dark cycle. Food (high-fiber rabbit diet 2031, Harlan, as well as fruits, vegetables, and hay) and water were provided ad libitum.
Pilot TD and FTD rabbit teratology studies. In an initial pilot study, pregnant does were given either a teratogenic dose of TD (400 mg/kg) (positive control) (n ¼ 3) or an equimolar dose of FTD (427 mg/kg) (n ¼ 2) or the vehicle control (1.5% CMC) (n ¼ 3) on GDs 8-12 using a novel buccal method of administration, which involved manually infusing the drug suspension from a 10-ml syringe attached to soft tubing protected by an outer metal tube into the back of the rabbit's throat and ensuring that swallowing ensued. TD and FTD were sonicated into suspension in 5 ml of cold 1.5% CMC and buccally infused within 5 min of preparation. To maximize compliance and minimize stress, a preconditioning procedure was employed in which rabbits were buccally administered the vehicle (CMC) and then rewarded with a small treat (vegetables/fruit) twice a day for 3 days (GDs 5-7) prior to the day of drug dosing. We observed that the does quickly habituated to the buccal dosing method and were accustomed to the technique by GD 8. TD-treated does were sacrificed on GD 29 by carbon dioxide (CO 2 ) asphyxiation and fetuses assessed for gross morphological anomalies and 2-h postpartum lethality, the latter measured as the number of pups that failed to survive a 2-h period inside a temperature-(37°C) and humidity-controlled incubator (1602N Thermal Air Hova-Bator, Georgia Quail Farm Manufacturing Company Inc., Savannah, GA). FTD at a dose equimolar to that for TD proved maternally toxic and lethal (see ''Results'' section), precluding assessments of teratological outcomes and postpartum lethality. Postmortem assessments of FTD-treated does were performed by a veterinary pathologist.
FTD mouse toxicity and teratology studies. To continue the rabbit teratology studies, a lower, nonlethal maternal dose of FTD was determined in pregnant CD-1 mice. Dams were orally gavaged on GDs 8-12 with 1173 (comparable to the 427 mg/kg dose used in rabbits, corrected for surface area to weight ratio), 586, or 440 mg/kg of FTD. FTD was sonicated into suspension in 500 ll cold 1.5% CMC and administered immediately after preparation. CMC alone was used as the vehicle control. Maternal weight gain was recorded on GDs 1, 8-12 (dosing period), and 19 prior to sacrifice. Tail vein blood was sampled continuously in the same dams at 0, 6, 12, and 24 h after the first drug dose on GD 8 for blood urea nitrogen (BUN) and plasma alanine aminotransferase (ALT), biomarkers of nephrotoxicity and hepatotoxicity, respectively. Maternal BUN and ALT levels were quantified using commercially available kinetic assay kits (Pointe Scientific Inc., Biopacific Ltd, Vancouver, Canada). Dams surviving treatment to GD 19 were sacrificed by cervical dislocation and fetuses removed for assessment of gross morphological anomalies, 2-h postpartum lethality and birth weight. Other pregnancy parameters assessed included the number of pups born alive or dead, late in utero deaths (classified as small white fetuses 2-3 mm long with primitive head, abdomen, and limb bud structures formed along with a placenta), and the number of resorptions (early embryonic in utero death) and implantation sites. Maternal brain, heart, lung, liver, and kidneys were removed at the time of sacrifice (or death in those dams that received the highest FTD dose), preserved in 10% formalin, sectioned, and stained with hematoxylin and eosin (H&E staining) for gross histopathological assessment.
TD and FTD disposition in rabbits. Nonpregnant female NZW rabbits (n ¼ 3 per treatment group) were buccally administered a single dose of either TD (150 mg/kg) or an equimolar, maternally nontoxic dose of FTD (160 mg/kg). The FTD rabbit dose was comparable to the lowest maternally nontoxic dose of 440 mg/kg FTD administered to mice when corrected for surface area. Both drugs were delivered as a suspension sonicated in 5 ml cold 1.5% CMC. To ensure maximal bioavailability, a companion study was conducted in nonpregnant does in which FTD was dissolved in a 30% Tween solution and within 2 min administered iv in a single 8 mg/kg dose (n ¼ 3). Ear vein blood was sampled at 0, 0.5, 1, 3, 6, 9, 12, 15, 21, 24, 28, 32 , and 36 h after dosing for measurement of plasma drug concentrations. Blood samples were collected in heparinized microsample collection tubes (Microvettes, Sarstedt, Canada), immediately centrifuged at 1000 3 g for 15 min at 4°C, and the plasma isolated and acidified with an equal volume (1:1) of Sorensen's citrate buffer (0.025M, pH 1.5) to prevent further spontaneous drug hydrolysis (Eriksson et al., 1995) . Plasma samples were stored at À20°C until drug extraction and analysis using HPLC coupled with ultraviolet detection (HPLC-UV).
TD and FTD hydrolysis in vitro. To determine why FTD, unlike TD, was not detectable in rabbit plasma after in vivo administration, the nonenzymatic rate of hydrolysis was determined in vitro. TD and FTD stock solutions were made up in methanol (MeOH) (390lM; 100 lg/ml) and added to the following aqueous matrices at a final concentration of 39lM (10 lg/ml): (1) 100mM KH 2 PO 4 buffer, pH 6.0; (2) 100mM KH 2 PO 4 buffer, pH 7.4; (3) plasma obtained from nonpregnant, untreated female NZW rabbits; and (4) rabbit ''embryo culture media'' (ECM) (see ''Materials and Methods, Rabbit embryo culture and dissection'' section for composition). All in vitro incubations were carried out at 37°C, with slow continuous mixing on a rocking platform. Aliquots (~100 ll) from each reaction were taken at 0, 5, 10, 15, and 30 min, followed by 1, 2, 3, 5, 6, 12, 24, 34, 48 , and 74 h after addition of the drugs, immediately acidified with an equal volume of Sorensen's citrate buffer to prevent further drug hydrolysis (Eriksson et al., 1995) , and stored at À20°C until drug extraction and HPLC-UV analysis.
TD and FTD extractions. TD and FTD were extracted and purified from the biological matrices (i.e., plasma samples and hydrolysis reactions in ECM) in preparation for HPLC-UV analysis. Immediately prior to extraction, PHEN or BGEE was added to samples containing TD or FTD, respectively, as internal standards. Samples were extracted three times with diethylether (5:1, vol/vol), vigorously vortexed for 1 min, briefly centrifuged at 16,000 3 g, and the organic layers pooled and evaporated under a steady stream of nitrogen (N 2 ) gas. Dried samples were reconstituted in MeOH and filtered through Microcon centrifugal filter units (YM-10, 10,000 MW cutoff, Millipore) (14,000 3 g, 25 min, 4°C).
HPLC-UV quantification of TD and FTD. TD and FTD were quantified using an isocratic Series 200 HPLC system (PerkinElmer Instruments LLC, Shelton, CT) connected to an integrator (PerkinElmer NCI 900 Interface) with a mobile phase of acetonitrile and double-distilled water (35:65, vol/vol) flowing at 0.8 ml/min. Samples were separated through a 5-lm C-18 column (15 cm 3 4.6 mm, Jones Chromatography Ltd) and TD/FTD quantified by UV detection at 220 nm. Chromatograms were analyzed using commercial software (TotalChrom chromatography software version 6.2.0, PerkinElmer Instruments LLC). TD/FTD in samples were confirmed by reference to pure standards and corrected for extraction yield using internal standards. Standard curves for TD, FTD, and their respective internal standards were constructed to determine the linear range of the assay. All TD/FTD samples were analyzed within the linear range of the assay.
Mass spectrometry. Mass spectrometry was used to verify the chemical identity and purity of TD, FTD, and the unknown metabolite produced after FTD incubations in ECM. The samples were run using a Sciex QStar quadrupole time-of-flight mass spectrometer (AB Sciex, Foster City, CA) with electrospray ionization. Samples were diluted in (1:1) 0.1% HCOOH:CH 3 OH to a concentration of~1 to 10lM, and approximately 1 ll of the sample solution was introduced to the mass spectrometer by loop injection at a flow rate of 100 ll/min. For TD and FTD, the mass spectrometer was operated in positive ion mode. For the unknown FTD metabolite, both positive and
Comparison of TD-initiated fetal anomalies and toxicities after buccal and oral gavage in NZW rabbits. Incidences of gross morphological anomalies, resorptions, and 2 h postpartum lethality, calculated as the mean incidence per litter, in GD 29 NZW rabbit fetuses after in utero exposure to TD (400 mg/kg) via buccal administration (solid gray bars) compared with published values using oral gavage (solid black bars) (Parman et al., 1999) . Buccally administered CMC served as the vehicle (Veh) control (clear bars). ''n'' Indicates the number of viable fetuses (anomalies and postpartum lethality) or implantations (resorptions) assessed per treatment group. ''NA'' indicates the parameter was not assessed. The number of does treated with TD was the same in this study and that by Parman et al. (1999) (N ¼ 3) . Asterisks indicate an effect of TD given buccally or via oral gavage from the Veh control (p < 0.05). Inset, scatter plots illustrating the variability in incidences of fetal anomalies and toxicities observed among litters after buccal administration of TD. Vertical lines indicate the mean incidence for each anomaly/toxicity. Teratological parameters on the vertical axis are the same as those for the main graph but abbreviated: anencephaly (An), encephalocele (En), phocomelia (Ph), bent limbs (BL), adactyly (Ad), bent digits (BD), gastroschisis (Gs), omphalocele (Om), resorptions (Res), and postpartum lethality (PpL). DEVELOPMENTAL TOXICITY OF FLUOROTHALIDOMIDE negative ion modes were used. Accurate mass analyses are provided within 5 ppm of the theoretical molecular mass of the analytes.
Male rat/rabbit serum for mouse/rabbit embryo culture. Male rat and rabbit serum, which contains unidentified nutrients essential for mouse and rabbit embryonic survival and growth in culture, were obtained from retired SpragueDawley rats (Charles River Laboratories International, Inc., Wilmington, MA) and NZW male rabbit breeders (Charles River Canada), respectively. Upon anesthetization with isoflurane, rats were exsanguinated via the vena cava and rabbits by cardiac puncture. Blood was collected into 10 ml BD Vacutainer tubes (BD Falcon, VWR International, Canada) and kept on ice. Upon complete exsanguination of all animals, blood was first centrifuged at 2000 3 g for 5 min and then at 3000 3 g for another 30 min at 4°C. The resulting serum was transferred, pooled, and heat inactivated at 56°C for 1 h. Rat serum was gassed until saturation with 5% CO 2 in air, whereas rabbit serum was gassed with 75% N 2 , 20% oxygen (O 2 ), and 5% CO 2 (Linde/BOC, Toronto, Ontario, Canada).
Mouse embryo dissection and culture. Pregnant CD-1 dams were sacrificed on GD 8 by cervical dislocation, and the uterus was removed and rinsed in HBSS. Embryos were explanted in warm 37°C HBSS and kept in ''holding media'' (HM, containing male rat serum:Waymouth's MB 752/1 medium [50:50 vol/vol], 50 U/ml penicillin-streptomycin, 2.5mM HEPES, and pre-gassed to saturation with 5% CO 2 in air) until dissection, at which time the decidua, trophoblast, and Reichert's membrane were removed using forceps (No. 5 watchmaker's type, Fine Science Tools Inc., North Vancouver, British Columbia, Canada) leaving the embryo, amnion, its surrounding visceral yolk sac (VYS), and the ectoplacental cone intact. CD-1 embryos with six somite pairs were selected for further culture, quickly washed in HM, and then immediately transferred into a 24-well plate (BD Falcon, untreated, VWR International, Canada) containing 2 ml mouse ECM (composed of male rat serum:Waymouth's MB 752/1 medium:-fetal bovine serum [1:1:1 vol/vol/vol], 50 U/ml penicillin-streptomycin, 2.5mM HEPES, and pre-gassed to saturation with 5% CO 2 in air). Immediately after preparation, appropriate drug treatments were added to plate wells before sealing and embryos were incubated for 24 h at 37°C on a rocking platform.
Rabbit embryo dissection and culture. Pregnant does were sacrificed on GD 9 by asphyxiation with CO 2 and the uterine swellings removed and rinsed in HBSS. Embryos were dissected in warm 37°C HBSS as previously described (Pitt and Carney, 1999a) . Briefly, a single vertical cut was made down the middle of the uterus swelling to expose the embryo. Vaness scissors (World Precision Instruments, Sarasota, FL) were used to detach the VYS from the underlying placental discs by cutting distally around the peripheral VYS vessel and gently peeling the embryo with its intact VYS off of the placental discs with forceps (Fine Science Tools Inc.). Embryos with 14-18 somite pairs, a beating heart, and a complete intact peripheral VYS vessel were selected for further culture. Explanted embryos were rinsed and immediately put into 2 ml rabbit ECM (containing male rabbit serum and Waymouth's MB 752/1 medium [75:25 vol/vol], 50 U/ml penicillin-streptomycin, 2 mg/ml L-glucose, 
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and pre-gassed to saturation with 75% N 2 , 20% O 2 , and 5% CO 2 ) and cultured in a sealed 24-well plate (untreated, BD Falcon, VWR International, Canada) with the appropriate drug treatments for 24 h at 37°C on a rocking platform. After 24 h in culture (on GD 10), embryos were transferred into 2 ml of fresh media (pre-gassed to saturation with 95% O 2 and 5% CO 2 ), drug treatments were reapplied, the plate resealed, and returned to 37°C on a rocking platform for a total culture period of 48 h.
TD and FTD treatments in embryo culture. Stock solutions of TD (117mM) and FTD were (125mM) made up in DMF immediately prior to addition to wells containing 2 ml ECM for a final embryonic exposure concentration of 117lM. DMF (0.1% vol/vol) served as the vehicle control. Stock and final embryo culture concentrations used were those of maximal solubility and limited by the low solubility of these drugs in aqueous media. CD-1 mouse embryos and NZW rabbit embryos exposed to an established embryopathic concentration of PHT (20 lg/ml, 80lM, 24 h) (Winn and Wells, 2002) and MAA (5mM, 48 h) (Pitt and Carney, 1999b) served as respective positive controls. Groups of untreated mouse and rabbit embryos exposed to 2 ml ECM per day only served as baseline controls for comparison to treatment groups.
Embryo culture: morphological, developmental, and functional assessment. After a 24-h culture period (GD 9), mouse embryos were assessed (1) for growth by measuring VYS diameter, crown-rump length (tip of midbrain to 13th somite at bottom of forelimb bud), and forelimb bud width (measured as number of somites spanned by the limb bud); (2) developmentally for anterior neuropore closure (ANC), turning, somite development, and forelimb bud development (morphological score 0-3); and (3) functionally for heart rate.
After a 48-h culture period, rabbit embryos were assessed on GD 11 (1) for growth as measured by head length (tip of snout to top of midbrain); (2) developmentally for the fore-, mid-, and hindbrain, optic and otic vesicles, heart, fore-and hindlimb bud, VYS closure, and flexion; and (3) functionally for heart rate. The numerical scoring system for developmental parameters was based on a protocol from Carney et al. (2007) .
Statistical analysis. Statistical significance between treatment groups was established using a commercial software program (Prism 3.0, GraphPad Software, San Diego, CA). Binomial data were analyzed using a chi-square test. Numerical data were analyzed using either a one-way ANOVA followed by the Tukey-Kramer posttest for comparison of more than two treatment groups or a two-tailed Student's t-test for comparisons between two treatment groups. Statistical significance was set at p < 0.05.
RESULTS

TD Administration Via a Novel Buccal Route Is Teratogenic
TD (400 mg/kg) administered buccally to pregnant NZW rabbits on GDs 8-12 produced no observable maternal toxicity but was highly teratogenic, causing similar incidences of limb defects but a wider spectrum of anomalies than typically reported for TD given via oral gavage (Parman et al., 1999) , a traditional route of administration that is more maternally stressful (Fig. 2) . Fetuses exposed to TD given buccally in utero exhibited higher incidences of anencephaly (47%), phocomelia (34%), adactyly (35%), gastroschisis (17%), and 2 h postpartum lethality (62%) compared with the vehicle control group (p < 0.05) (Fig. 2 and  Supplementary fig. S1 ). Encephalocele (16%), bent or abnormal limbs/digits (27%), omphalocele (16%), and resorptions (18%) also appeared to be increased by buccal TD treatment, but these effects were not statistically significant compared with the vehicle control group (Fig. 2) . These results validated the novel buccal route of exposure, which was subsequently used for FTD in the rabbit teratology studies.
FTD Is Maternally Toxic and Lethal in Rabbits
In contrast to TD, an equimolar dose of FTD (427 mg/kg, buccal) was maternally toxic and lethal in pregnant rabbits. Both does given FTD developed a persistent unidentified green stain observed near the nostrils and mouth within the first 2 days of dosing, followed by rapid weight loss (> 10% original body weight) and vaginal bleeding. The two FTD-treated does (X/Y) indicates the number of dams that died of FTD-initiated toxicity prior to GD 19 (end of study) out of the total number of dams that were assessed for organ toxicity in each treatment group. Asterisks indicate a difference from Veh control (p < 0.05).
DEVELOPMENTAL TOXICITY OF FLUOROTHALIDOMIDE died 3 and 9 days (on GDs 15 and 21), respectively, after the end of the dosing period. Postmortem assessments revealed remnants of macerated fetuses and signs of maternal pulmonary edema and renal tubular degeneration.
FTD Maternal Toxicity Profile and Dose Optimization in Mice
The death of the two pregnant rabbits necessitated the use of a lower FTD dose, which was established in mice. The same maternally lethal dose of FTD in rabbits, when adjusted for body surface area to weight ratio and administered to pregnant mice, was similarly lethal, and in mouse dose-ranging studies, FTD caused a significant dose-dependent decrease in both maternal survival and weight gain throughout gestation. Dams receiving the two highest FTD doses (1173 and 586 mg/kg) had 20 and 73% 1-week survival rates, respectively (Fig. 3, top panel) . The highest FTD dose also decreased maternal weight gain on GDs 16-19 by about 30% compared with vehicle controls (p < 0.05) (Fig. 3, bottom panel) , with dams showing symptoms of toxicity prior to death similar to those observed in rabbits. The lower FTD dose (440 mg/kg) proved nontoxic, with maternal survival and weight gain similar to vehicle-treated dams, and this dose 162 adjusted for body surface area to weight ratio was used in subsequent rabbit studies. Maternal BUN and plasma ALT levels were not significantly elevated up to 24 h after the first dose in any of the FTD-treated groups (Figs. 4A and 4B ), although histopathological examination revealed a 50% incidence of nephrotoxicity in dams treated with the highest FTD dose (p < 0.05) (Fig. 4C) . Compared with the medium dose of FTD (586 mg/kg), the highest FTD dose (1173 mg/kg) caused a 2.9-fold increase in the incidence of dams exhibiting histopathological evidence of nephrotoxicity and approximately the same incidence exhibiting pulmonary toxicity (50 vs. 67%), with no evidence of hepatotoxicity compared with a nonsignificant 17% incidence with the medium dose. Interestingly, there was an apparent 67% lower incidence of dams exhibiting cardiac toxicity following the high dose of FTD (17%, nonsignificant) compared with the lower dose (50%, p < 0.05) (Fig. 4C) . The apparently similar incidence of dams with pulmonary toxicity and lower incidence with cardiac toxicity caused by the highest versus medium doses of FTD may have been due in part to differences in the severity of unrecognized maternal organ damage and/or the earlier death of the majority of dams (four of six) treated with the highest FTD dose, which may not have allowed enough time for the manifestations of toxicity. Dams treated with the lowest dose of FTD (440 mg/kg) had organ histology comparable to those of the vehicle treatment group.
FTD Fetal Toxicity in Mice
The highest FTD dose (1173 mg/kg) caused an apparent decrease in percentage of pups born alive and fetal weight, along with an increase in resorptions and 2-h postpartum lethality compared with vehicle-treated litters (Fig. 5) , although an actual statistical comparison between this dose and the other treatment groups could not be made as only two dams survived throughout the entire gestation. Fetal weight was decreased in an FTD dose-dependent manner (p < 0.05) (Fig. 5) . No fetal toxicity or anomalies were detected using the lowest FTD dose (440 mg/kg).
TD and FTD Quantification by HPLC-UV
Standard curves for both TD and FTD quantified by HPLC-UV showed linearity from 2 lg to 2 mg, whereas the internal standards PHEN and BGEE showed linearity from 2 lg to 2 mg and 1-100 lg, respectively (data not shown). Under our specified HPLC-UV conditions, the pure standards of TD and PHEN had average retention times (R t ) of 4.7 and 5.4 min, respectively; FTD and BGEE standards had average R t values of 4.9 and 10.6 min, respectively (data not shown).
FTD Rapidly Breakdowns In Vivo
Nonpregnant female NZW rabbits given a single oral dose of TD (150 mg/kg, buccally) exhibited a mean peak plasma concentration (C max ) of 11.4 ± 2.0 lg/ml achieved between 9 and 12 h, with a mean in vivo half-life (t 1/2 ) of 3.9 ± 0.4 h (Supplementary fig. S2 ). In contrast, plasma FTD concentrations were nondetectable as early as 30 min after a single equimolar dose of FTD (160 mg/kg, buccally) and remained so up to 36 h after drug administration (Supplementary fig. S2 ). Similarly, FTD could not be detected at any time point (30 min to 36 h) in plasma after a single iv injection of the drug (8 mg/kg) (data not shown).
FTD Rapidly Hydrolyzes In Vitro
To determine why FTD was not detectable in plasma following in vivo administration, the nonenzymatic hydrolysis rates for FTD and TD were determined in vitro. Spontaneous hydrolysis of TD in phosphate buffers at pH 6.0 and 7.4 and in rabbit plasma and ECM had t 1/2 values of 15.4, 2.2, 1.1, and 1.1 h, respectively (Fig. 6) . By comparison, FTD hydrolyzed at a six-to 22-fold FIG. 6 . In vitro TD and FTD hydrolysis. Incubations of TD (squares) and FTD (circles) were carried out in pH 6.0 and 7.4 KH 2 PO 4 buffers as well as in rabbit plasma and ECM at 37°C. TD and FTD were quantified by HPLC-UV at 220 nm to calculate drug half-lives (t 1/2 ). DEVELOPMENTAL TOXICITY OF FLUOROTHALIDOMIDE faster rate, with t 1/2 of 2.3 h, 10, 3, and 5 min, respectively, under the same in vitro conditions (Fig. 6) . Both TD and FTD hydrolyzed faster under more basic (higher pH) conditions.
In incubations with TD in pH 6.0 phosphate buffer, the slow formation of an uncharacterized hydrolysis product (HP-0.7) was detectable at 220 nm, with a R t value of 4.0 min (Supplementary figs. S3 and S4) . Similarly, in incubations with FTD, the gradual formation of two uncharacterized HPs (HP-2.5 and HP-1.7) could be detected, with R t values of 4.3 and 5.7 min, respectively (Supplementary figs. S3 and S4).
In blank rabbit plasma and ECM spiked with pure standards, TD and FTD had R t values of 4.3 and 5.1 min, respectively (Supplementary fig. S5 ). FTD incubations in ECM showed the formation of an unknown metabolite with an average R t of 4.0 min, similar to that of TD (Supplementary fig. S5 ). However, although mass spectrometry was unable to confirm the chemical identity of this metabolite, its spectrum was not that of TD, which has a similar R t (data not shown).
FTD Is Nonembryopathic in Mouse Embryo Culture
CD-1 mouse embryos exposed to an embryopathic concentration of PHT (80lM, 24 h) (positive control) had decreased ANC, turning, and somite development (p < 0.05) (Fig. 7) as previously reported (Winn and Wells, 2002) , validating our embryo culture technique and the use of PHT as a positive control. Similar to complementary murine TD studies (Lee et al., 2011b) , FTD (117lM, 24 h) was nonembryopathic in mouse embryo culture, with no effects on limb bud development (Figs. 7 and 8 ).
FTD Initiates Hindbrain and Optic Vesicle Embryopathies in
Rabbit Embryo Culture Rabbit whole embryo culture has previously been established as a relevant and sensitive model for in vivo TD embryopathies (Lee et al., 2011a) , whereby TD in culture caused decreases in head length, fore-and hindbrain, and limb bud development by up to 77% (p < 0.05). In contrast, an equimolar concentration of FTD (117lM, 48 h), although specifically decreasing hindbrain and optic (eye) vesicle development by 19 and 24%, respectively, compared with DMF vehicle control rabbit embryos (p < 0.05), had no effect on any other parameters, particularly including limb bud growth and development, the hallmark of TD embryopathies (Figs. 9 and 10) . 
DISCUSSION
Expanding clinical use of TD as an anti-inflammatory, immunomodulatory, and anticancer agent (Franks et al., 2004) has been limited by emerging new cases of teratogenesis (birth defects) (Castilla et al., 1996; Schuler-Faccini et al., 2007) . Consequently, there is continuing interest in the possibility that the therapeutic effects of TD might be stereoselectively dissociated from its teratogenic effects by the use of the appropriate TD isomer. An early study reported that R-TD caused central nervous system depression in rats at a twofold lower dose than S-TD; however, this endpoint was assessed 4-15 h after dosing (Fabro et al., 1967b) , beyond the 2-4 h required for a pure isomer to spontaneously racemize in plasma to equal parts R and S-TD (Eriksson et al., 1995) . More recently, TD-induced sedation in humans was reported to correlate with plasma concentrations of the R isomer, whereby subjects infused with R-TD felt tired immediately, as distinct from a relative lag time when given S-TD, which corresponded to the timing of in vivo conversion of S-TD to the R isomer in plasma (Eriksson et al., 2000; Hoglund et al., 1998) . On the other hand, the S isomers of TD, EM-12 (a more potent teratogenic derivative with racemizing isomers), and Me-TD (nonracemizing isomers) show greater ability to inhibit TNF-a induction than their corresponding R isomers after 6-18 h in cell culture Niwayama et al., 1998; Wnendt et al., 1996) . However, these studies did not determine the extent of racemization or hydrolysis, which occurs fairly rapidly for TD in vivo (t 1/2 ¼ 3 and 2 h, respectively, in humans) (Eriksson et al., 1995) , and reports of stereoselectivity for the TNF-a effects of TD are inconsistent, as the same cells treated with a different TNF-a inducer reported that the opposite isomer (R-TD) preferentially inhibited TNF-a production (Miyachi et al., 1996) . Finally, literature claims for S-TD being the more teratogenic isomer are based upon a few questionable studies; namely, (1) a study that found S-TD caused a mere 2% more malformations than R-TD in rabbits (Fabro et al., 1967b) ; (2) a report of S-TD and not the R isomer being teratogenic but in mice, a species known to be resistant to TD teratogenesis (Blaschke et al., 1979) ; and (3) experiments with EM-12, which also racemizes at a rate similar to that for TD in vivo in monkeys Merker et al., 1988) . At best, the above studies suggest that at least some of the therapeutic and teratogenic effects of TD may be stereoselectively dissociable, but rapid racemization together with rapid TD hydrolysis makes it impossible to unequivocally attribute these effects to a single isomer of TD (Eriksson et al., 1995) .
FTD, the closest structural analog of TD, has stable, nonracemizing isomers that offer a potentially unambiguous approach for assessing the stereoselective nature of TD effects. Cell culture studies have shown that FTD is both a potent and stereoselective TNF-a inhibitor Takeuchi et al., 1999) , but neither these results nor the toxicological effects of FTD have been examined in vivo. Herein we report the first in vivo characterization of maternal and developmental effects of FTD in rabbits and mice, two species, respectively, susceptible and resistant to TD teratogenesis (Schumacher et al., 1968) .
In a pilot rabbit teratology study, we developed and validated a novel buccal route of TD administration. In rabbits, oral gavage via a flexible tube inserted into the stomach is the most common method of TD delivery that consistently produces limb defects relevant to the human TD syndrome (Parman et al., 1999; Somers, 1962) ; however, gavage is technically challenging and often stressful for pregnant does, increasing the likelihood of litter abortion. By comparison, our buccal technique for TD administration, in which the drug is infused into the mouth, proved a less stressful procedure, to which pregnant rabbits quickly habituated, and resulted in a full spectrum of relevant TD anomalies including limb defects, with incidences equal to or greater than those with the gavage route. Buccal administration of an established teratogenic dose of TD (400 mg/kg) during the sensitive period of organ formation (organogenesis) caused a 34% incidence of limb anomalies, comparable to that seen with oral gavage (35%) (Parman et al., 1999) using the same dose. In adult humans and animals, TD has an extremely safe acute toxicity profile in susceptible and resistant species alike (Williams, 1968) . Similarly, in our studies, pregnant does treated with a 400 mg/kg dose of In contrast, rabbits treated with an equimolar dose of racemic FTD (427 mg/kg) experienced overt maternal toxicity characterized by presence of green staining around the nose and mouth, lethality, and total litter resorption, precluding fetal assessments. Similar toxicity and lethality also occurred in pregnant CD-1 mice treated with a comparable dose of FTD adjusted for body surface area to weight ratio, suggesting that the mouse was a suitable species for dose-ranging studies to establish a maternally safe dose in rabbits.
The unexpected potent in vivo toxicity associated with FTD might be explained by the fluorine substitution, which typically for many drugs (1) increases lipophilicity leading to greater oral absorption and bioavailability, (2) provides chemical stability thereby inhibiting/slowing metabolic breakdown, and (3) creates compounds with higher affinity for their target receptors, thereby extending and/or accentuating receptor-mediated therapeutic effects (Park et al., 2001) . Fluorination is often used as a method for enhancing pharmacological potency of drugs but may also inevitably increase toxicity (Park et al., 2001 ). This appears to be the case for FTD, as well as other fluorinated analogs of TD, which exhibit enhanced TNF-a inhibitory activity in cell culture, but are also up to 1000-fold more cytotoxic than TD itself Miyachi et al., 1998; Ng et al., 2003) . The only other study that has evaluated FTD in vivo, in this case as an anticancer agent, also reported weight loss and lethality (not quantified) in C57BL/6 mice after a 20 mg/kg, ip dose (Chung et al., 2003) , which is in agreement with the maternal toxicity and lethality caused by FTD herein. A hexafluorinated TD FIG. 9 . Embryopathic effects of FTD on the head, heart, and limb buds in rabbit embryo culture. GD 9 NZW rabbit embryos were exposed in culture to either 117lM of TD or FTD or their DMF vehicle for 48 h (GDs 9 and 10). A group of untreated embryos grown in ECM only served as a baseline control. The number of does and embryos (N,n) indicated in the top panel apply to all other parameters. Asterisks indicate an embryopathic effect compared with the DMF vehicle (p < 0.05).
166 LEE ET AL. derivative (CPS 49) also proved to be highly toxic to mice in vivo, causing 100% lethality at 200 mg/kg (Ng et al., 2003) .
Although FTD proved more toxic than TD, we were nonetheless able to determine a lower maternally nontoxic FTD dose (440 mg/kg) that, similar to TD, was also nonteratogenic in mice. The rabbit equivalent of this FTD dose (160 mg/kg, corrected for surface area to weight ratio), intended for further teratology studies, was first given to nonpregnant does to confirm its safety and monitor plasma drug concentrations. TD-treated rabbits serving as a positive control group had plasma drug concentrations and half-lives (t 1/2 ) similar to literature values (Fabro et al., 1967a) . Surprisingly, FTD was undetectable in plasma as early as 30 min after both oral and iv administration, suggesting rapid in vivo breakdown via nonenzymatic hydrolysis at the amide bonds. Hydrolysis is the primary route of TD degradation in vivo in all species, giving rise to a multitude of wellidentified TD HPs (Fabro et al., 1967a; Williams, 1968) .
In vitro incubations of FTD in pH 7.4 buffer confirmed our in vivo findings, wherein FTD spontaneously hydrolyzed at a rate 13-fold faster than TD, resulting in at least two detectable HPs. The in vitro rate of FTD breakdown was further accentuated in rabbit ECM and plasma, up to 22-fold faster than TD, possibly catalyzed by serum proteins, as was seen with TD, resulting in a t 1/2 for FTD in the order of 3-5 min. Although nonenzymatic hydrolysis of FTD was predictable based upon its structural similarity to TD, the ultrarapid rate was unexpected and may be due to the strong electron withdrawing effects of the fluorine atom (Park et al., 2001) , making the amide bonds of the compound more prone to hydrolysis. This is the first report on the chemical stability of FTD both in vitro and in vivo. Its ultrarapid hydrolysis has important implications for the existing literature on FTD pertaining to its potent stereoselective anti-TNF-a activity and in vivo toxicity (Chung et al., 2003; Man et al., 2003; Takeuchi et al., 1999) , as well as for future studies using this or other fluorinated analogs, because any reported effects may in fact be due to extensively formed HPs rather than the parent compound. Given the chemical instability of FTD, we proceeded to evaluate its developmental effects and/or those of its rapidly formed HPs in an embryo culture system. This approach allows for direct assessment on a whole developing embryo with the added advantages of precise control over the concentration, duration, and gestational period of drug exposure, while avoiding complicating and confounding in vivo maternal/placental factors (Webster et al., 1997) . Moreover, embryo culture is an established sensitive, species-and tissue-specific model for TD teratogenesis, in which TD causes limb bud embryopathies relevant to the human TD syndrome in rabbit but not mouse embryos (Lee et al., 2011a,b) . Similar to TD, FTD was nonembryopathic and did not affect limb bud development in cultured CD-1 mouse embryos, although mouse embryos were sensitive to the embryopathic effects of the positive control, PHT. In cultured rabbit embryos, FTD attenuated hindbrain and optic (eye) vesicle development, but unlike TD, which severely attenuated limb bud development by up to 77%, FTD failed to initiate any limb bud embryopathies. Results from this final study suggest that although FTD may be teratogenic, it exhibits tissue/organ specificity different from that of TD, making it a qualitatively inappropriate model for TD teratogenesis, in addition to the problems of its high chemical instability and maternal toxicity. The remarkable differences in the chemical and toxicological properties of FTD and TD revealed herein also suggest that the use of other fluorinated derivatives and analogs of TD, including hexafluorinated derivatives (Therapontos et al., 2009) , as models for elucidating mechanisms of TD teratogenicity should be interpreted with caution.
Despite the drawbacks of FTD addressed in the study herein, the remarkably potent and universal toxicity of FTD and/or its HPs in both the dams and embryos of rabbits and mice might prove therapeutically useful in other contexts, such as killing tumor cells. More detailed investigations into the molecular mechanisms underlying these broad toxic effects of FTD may reveal new uses for this compound, as well as provide insights into the pathways involved in drug toxicity.
In conclusion, in comparison to TD in vitro, in vivo, and in embryo culture, FTD was highly chemically unstable, exhibited 
